| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenue | 39,143 | - | - | - |
| Salaries | 235,190 | - | - | - |
| Consumables | 92,725 | - | - | - |
| Platform | 36,934 | - | - | - |
| Discovery | 58,716 | - | - | - |
| Clinical development | 33,338 | - | - | - |
| Depreciation and amortization | 64,223 | - | - | - |
| Other segment items | 57,815 | - | - | - |
| Loss from operations | -539,798 | - | - | - |
| Other non-operating income (loss), net | 3,005 | - | - | - |
| Income tax benefit (expense) | -156 | - | - | - |
| Net loss | -536,637 | -374,384 | -202,487 | -284,755 |
| Depreciation and amortization | 64,223 | 43,180 | 19,331 | 23,543 |
| Stock-based compensation | 87,460 | 62,217 | 36,058 | 50,904 |
| Asset impairment | 5,956 | 5,956 | 5,956 | 108 |
| Lease expense | 17,019 | 11,755 | 6,130 | 11,155 |
| Loss on disposal of a business | -4,502 | -4,502 | -4,502 | - |
| Acquired ipr&d | 22,082 | - | - | - |
| Other, net | -6,655 | -9,098 | -4,405 | 650 |
| Other receivables and assets | -33,775 | -30,246 | -4,839 | 1,243 |
| Prepaid data assets | -29,601 | -29,601 | -27,131 | - |
| Accrued data liability | 20,258 | 20,258 | - | - |
| Unearned revenue | -30,014 | -23,383 | -9,762 | -22,374 |
| Accounts payable | -7,035 | -1,145 | 3,692 | -1,687 |
| Accrued development expense | -4,210 | -155 | 599 | -2,623 |
| Accrued expenses and other current liabilities | -23,246 | -15,213 | -26,591 | -5,001 |
| Lease liabilities | -16,124 | -10,908 | -5,760 | -11,121 |
| Net cash used in operating activities | -325,735 | -208,375 | -131,957 | -243,744 |
| Net cash and restricted cash acquired in the acquisition of a business | - | - | - | 0 |
| Purchases of property and equipment | 5,225 | 4,982 | 1,832 | 12,397 |
| Purchase of an intangible asset | 2,158 | 2,158 | - | 3,000 |
| Decrease in cash related to disposal of a business | -4,438 | -4,438 | -4,438 | - |
| Sales and maturities of investments | - | - | - | 0 |
| Purchases of investments | 3,806 | 1,500 | 1,000 | - |
| Net cash used in investing activities | -15,627 | -13,078 | -7,270 | -15,397 |
| Proceeds from issuance of common shares, net of issuance costs | 395,484 | 141,024 | 41,024 | 289,387 |
| Proceeds from equity incentive plans | 3,300 | 4,293 | 1,550 | 6,433 |
| Repayment of long-term debt and finance lease liabilities | 6,258 | 4,131 | 2,047 | 2,339 |
| Purchase of an intangible asset | 3,000 | 3,000 | - | - |
| Net cash provided by financing activities | 389,526 | 138,186 | 40,527 | 293,481 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 15,957 | 14,088 | 4,833 | 66 |
| Net change in cash, cash equivalents and restricted cash | 64,121 | -69,179 | -93,867 | 34,406 |
| Cash and cash equivalents at beginning of period | 603,024 | 603,024 | 603,024 | 401,425 |
| Cash and cash equivalents at end of period | 667,145 | 533,845 | 509,157 | 435,831 |
RECURSION PHARMACEUTICALS, INC. (RXRX)
RECURSION PHARMACEUTICALS, INC. (RXRX)